CDK4 and non-small cell lung carcinoma: All of these mechanisms provide a theoretical basis for the combination therapy of CDK4/6 inhibitors and immune checkpoint inhibitors in NSCLC in the future and related clinical trials (NCT03601598) are ongoing at present (43).